Clinical Research Directory
Browse clinical research sites, groups, and studies.
GDNF Gene Therapy for Parkinson's Disease
Sponsor: Brain Neurotherapy Bio, Inc.
Summary
The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
Official title: Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease
Key Details
Gender
All
Age Range
35 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
11
Start Date
2020-04-01
Completion Date
2027-06
Last Updated
2025-09-19
Healthy Volunteers
No
Conditions
Interventions
AAV2-GDNF
Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Locations (3)
University of California Irvine
Irvine, California, United States
University of California San Francisco
San Francisco, California, United States
The Ohio State University Medical Center
Columbus, Ohio, United States